Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273619 | 0.86 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL30602605 | 0.86 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL505643 | 0.83 | RAB9A (0.66) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1742147 | 0.82 | RAB9A (0.66) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10488542 | 0.81 | RAB9A (0.71) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1999435 | 0.81 | RAB9A (0.90) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL17278899 | 0.80 | HSD17B10 (0.54) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL11996369 | 0.79 | RAB9A (0.87) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL8554591 | 0.79 | RAB9A (0.87) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL2147069 | 0.78 | RAB9A (0.69) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168005-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | National Health Research Institutes (TW) | 2023-04-26 | — | — | EP | disclosed |
| EP-3145922-B1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | MOLECULAR TARGETING TECH INC (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021262628-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-12-30 | — | — | WO | disclosed |
| CN-106660992-B | Dimethylpyridine derivative and medical application thereof | 美泰康公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3145922-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | Molecular Targeting Technologies, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9388193-B2 | Dipicolylamine derivatives and their pharmaceutical uses | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2016-07-12 | — | — | US | disclosed |
| US-9388193-B2 | Dipicolylamine derivatives and their pharmaceutical uses | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2016-07-12 | — | — | US | disclosed |
| US-9388193-B2 | Dipicolylamine derivatives and their pharmaceutical uses | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2016-07-12 | — | — | US | disclosed |
| WO-2015179299-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | MOLECULAR TARGETING TECHNOLOGIES, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150336976-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | NAT HEALTH RESEARCH INSTITUTES (TW) | 2015-11-26 | — | — | US | disclosed |
| US-20150336976-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | NAT HEALTH RESEARCH INSTITUTES (TW) | 2015-11-26 | — | — | US | disclosed |
| WO-2015179299-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | MOLECULAR TARGETING TECHNOLOGIES, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336976-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | PTDSS2, PTDSS1, ITPR2 | RAB9A 2684/4885MAPT 3242/4885SMN1; SMN2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.